Brief: Phathom Pharmaceuticals Q2 Net Income USD -75.81 Million

Phathom Pharmaceuticals

07/08/2025 12:00

Overview

Phathom Q2 2025 revenue of $39.5 mln beats analyst expectations, per LSEG data

Company reports 49% growth in VOQUEZNA prescriptions since last earnings report

Phathom expects full-year 2025 revenue of $165 mln to $175 mln

Outlook

Phathom expects 2025 revenue between $165 mln and $175 mln

Company aims for profitability in 2026

Phathom anticipates non-GAAP operating expenses under $60 mln in Q3 2025

Company sees generic competition for VOQUEZNA unlikely before 2033

Result Drivers

PRESCRIPTION GROWTH - 49% increase in VOQUEZNA prescriptions since last earnings report

COMMERCIAL STRATEGY - Shifted focus to high-value prescribers, particularly gastroenterologists

MARKET EXCLUSIVITY - Extended exclusivity for VOQUEZNA expected to support market position

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$39.50 mln
$36.10 mln (8 Analysts)
Q2 EPS
-$1.05
Q2 Net Income
-$75.81 mln
Q2 Basic EPS
-$1.05


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $18.50, about 53.1% above its August 6 closing price of $8.68

Press Release: ID:nGNXbRW3Lg

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)